Multiple officers hospitalized after responding to illegal car meetup
Argument over loud music leads to shooting, barricade: police
Company linked to Alex Jones doubles offer to buy Infowars after failed bankruptcy auction
Ryanair calls for alcoholic drink limit at EU airports amid legal action against unruly passenger
Lasers help archaeologists study ancient tattoos on Peruvian mummies
‘God willing, it will end’: Gazans reflect on potential Israel-Hamas ceasefire deal
Elon Musk says a third patient got a Neuralink brain implant. The work is part of a booming field
IRS is sending out automatic stimulus payments. Who is getting them?
Boat sinks in lake: 3 people rescued, 1 dead, officials say
(Reuters) - Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.
The deal will give Gilead access to CymaBay's lead drug candidate called seladelpar for the treatment of primary biliary cholangitis, a type of chronic inflammatory liver disease.
CymaBay had submitted a marketing application to the U.S. Food and Drug Administration (FDA) for the drug in December.
Shares of CymaBay were halted ahead of the announcement in premarket hours.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)
